Petros Pharmaceuticals

Historical price data

Petros Pharmaceuticals is a commercial-stage company with a singular focus on expanding consumer access to medication through the Rx-to-OTC switch pathway. Founded in 2021 via a reverse merger, it aims to leverage regulatory expertise and consumer studies to convert prescription assets into OTC products, thereby reducing healthcare costs and improving health equity. Its strategy hinges on navigating complex FDA advisory processes and repositioning former prescription drugs for direct-to-consumer retail channels.

Expertise in the Rx-to-OTC switch regulatory pathway, focusing on FDA advisory processes, consumer behavior studies, and consumer-friendly labeling for safe self-medication.

Competes against large consumer health conglomerates (e.g., Kenvue, Bayer) and pharma companies with OTC divisions that have greater resources. Its niche is as an agile, pure-play specialist, but it must secure assets and navigate regulatory hurdles better than deep-pocketed rivals.